Significant p-values are highlighted in bold (p<0.05) (peaks 2, 3, 4, 5, 6, 7, 8, 9, 10 and S2 are significantly decreased and peaks 11, 12, 14, 15, 17, 18, S3B and S4 are significantly increased).
Epigenetic modifiers are promising targets to improve therapies in patients with cancer. Targeting the methyltransferase DOT1L with small molecule inhibitors has shown promising effects on the control